ARTICLE | Clinical News
Bridion sugammadex regulatory update
December 21, 2015 8:00 AM UTC
FDA approved Bridion sugammadex from Merck to reverse the effects of neuromuscular blockade induced by muscle relaxants rocuronium or vecuronium in adults undergoing surgery. Merck plans to launch the cyclodextrin derivative next month, at which time the pharma will disclose the drug’s price. ...